<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845153</url>
  </required_header>
  <id_info>
    <org_study_id>Metformin on Fracture healing</org_study_id>
    <nct_id>NCT03845153</nct_id>
  </id_info>
  <brief_title>Metformin Effect on Fracture Healing in Post-Menopausal Women</brief_title>
  <official_title>Study of Metformin Drug Effect on Fracture Healing in Post-Menopausal Women and Its Correlation to Serum Irisin Myokine Level.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      study the effect of metformin drug on fracture healing of patients with high risk of delayed
      fracture healing or non-union and correlating this to serum irisin myokine level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Approval will be obtained from Ethics Committee of general organization of teaching
           hospitals and institutes and Research Ethics Committee of Faculty of Pharmacy, Damanhour
           University.

        2. Getting informed consent from all participants to take part in this study.

        3. Two groups each of 20 post-menopausal women with a bone fracture. One group will be
           treated randomly with metformin Retard 850 mg once daily for two weeks then 850 mg twice
           daily. The other group will be untreated and served as control group.

        4. Venous blood samples will be taken from each patient before fracture stabilization and
           later for determination of serum irisin level with corresponding radiological
           evaluations.

      Inclusion criteria:

      • Age range from 55 to less than 65 years old with bone fracture.

      Exclusion criteria:

        -  Age equal or less than 55 years

        -  Age equal or more than 65 years

        -  Unstable or hospitalized patients with heart failure

        -  Hepatic impairment

        -  Chronic kidney disease with eGFR &lt;45 mL/minute/1.73 m2

        -  Open fractures

        -  Pathological fractures

        -  Diabetic patients Statistical tests appropriate to the study design will be conducted to
           evaluate the significance of the results.

      Methodology:

        -  Active Human Irisin ELISA kit will be used.

        -  Bone-specific Alkaline phosphatase BAP

        -  Serum creatinine, serum albumin, prothrombin time.

        -  Fasting insulin, fasting blood glucose and Calcium level.

        -  BMI, weight, waist, waist-hip ratio, total cholesterol and low-density-lipoprotein
           cholesterol.

        -  radiological scoring system will be used to evaluate the degree of new bone formation in
           the fracture line on anterior-posterior and lateral radiographs will be taken two months
           post stabilization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>40 post-menopausal women with a bone fracture divided into two groups each of 20, randomly assigned to administration with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily or with placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blind perspective study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Human Irisin (ng/ml)</measure>
    <time_frame>three months</time_frame>
    <description>myokine/adipokine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone specific alkaline phosphatase (IU/L)</measure>
    <time_frame>three months</time_frame>
    <description>isoenzyme produced by osteoblasts involved with calcification of skeleton and bone formation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative X-rays - Lane and Sandhu radiological scoring system</measure>
    <time_frame>two months post stabilization.</time_frame>
    <description>evaluate the degree of new bone formation in the fracture line on anterior-posterior and lateral radiographs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bone Fracture</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 post-menopausal women with a bone fracture treated with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 post-menopausal women with a bone fracture treated with placebo once daily for two weeks then twice daily for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Retard 850 mg</intervention_name>
    <description>tablet</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range from 55 to less than 65 years old with bone fracture.

        Exclusion Criteria:

          -  Age equal or less than 55 years

          -  Age equal or more than 65 years

          -  Unstable or hospitalized patients with heart failure

          -  Hepatic impairment

          -  Chronic kidney disease with eGFR &lt;45 mL/minute/1.73 m2

          -  Open fractures

          -  Pathological fractures

          -  Diabetic patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>post-menopausal women</gender_description>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gamal Omran, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rehab H Werida, Lecturer</last_name>
    <phone>00201005359968</phone>
    <email>rehabwerida@yahoo.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damanhour Medical National Institute</name>
      <address>
        <city>Damanhūr</city>
        <state>El-Bahairah</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rehab Werida</last_name>
      <phone>1005359968</phone>
      <email>Rehab_werida@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mahmoud H Kandil, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Fracture</keyword>
  <keyword>Post-Menopausal Women</keyword>
  <keyword>Metformin</keyword>
  <keyword>Irisin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

